1-3 of 3
Dae Young Zang, MDPhD
Close
Sort by
Journal Articles

Clinical Response Evaluation Toward Individualizing the Starting Dose of Dasatinib in Asian Patients with Chronic Myeloid Leukemia

Hyejin Shin, Jung-Eun Ha, Dae Young Zang, MDPhD, Sung-Hyun Kim, MD PhD, Young Rok Do, PhDMD, Won Sik Lee, MD PhD, Soo-Hyun Kim, Kyung-Mi Kee, Seon-Young Yang, So-Yoon Hwang, Eun-Jung Jang, Jangik Lee, PharmD, Dong-Wook Kim, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6.
https://doi.org/10.1182/blood-2020-140626
Published: 2020
Journal Articles

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Sung-Eun Lee, MD PhD, Joon Seong Park, MD, Young Rok Do, PhDMD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MDPhD, Sukjoong Oh, MDPhD, Jae-Yong Kwak, Jeong-A Kim, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Dong-Wook Kim, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 51–52.
https://doi.org/10.1182/blood-2020-139253
Published: 2020
Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Young Rok Do, PhDMD, Jae-Yong Kwak, MD PhD, Hawk Kim, MDPhD, Jeong-A Kim, MD PhD, Hyeoung-Joon Kim, MD PhD, Joon Seong Park, MD, Jooseop Chung, MD PhD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Udomsak Bunworasate, MD, Chul Won Choi, MD PhD, Narcisa Sonia Cornejo Comia, MD, Dae Young Zang, MDPhD, Sukjoong Oh, MDPhD, Saengsuree Jootar, MD, Ary Harryanto Reksodiputro, MDPhD, Won-Sik Lee, MD, Yeung-Chul Mun, MD PhD, Jee Hyun Kong, MD, Priscilla B. Caguioa, MD, Jinny Park, MD PhD, Chul W. Jung, MD PhD, Dong-Wook Kim, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1733.
https://doi.org/10.1182/blood-2018-99-110568
Published: 2018